Companies
(73)
AAC Clyde Space
ALM Equity
Alzinova
Arion Bank
Arlandastad Group
Ascelia Pharma
Bactiguard
Bergman & Beving
Besqab
BioPorto
Björn Borg
Bokusgruppen
Bonava
BTS Group
Byggmästaren
CAG Group
Calviks
Carasent
CDON
Clavister
Clemondo Group
eEducation Albert
Elanders
Elicera Therapeutics
Eolus
Ependion
EQL Pharma
Faron Pharmaceuticals
FluoGuide
Gentoo Media
GiG Software
HAKI Safety
HANZA
Iconovo
Idun Industrier
InfraCom
Initiator Pharma
Intervacc
ITAB Group
Kebni
Lifecare ASA
Lindex Group
Logistri
Lumi Education Group
Lytix Biopharma
Medivir
Mentice
Micro Systemation
MilDef Group
Net Insight
Nordic LEVEL Group
Orexo
Ortoma
OssDsign
Paxman
Pierce
PowerCell
Pricer
Qualisys
Relais Group
SaltX
Scanfil
Sensys Gatso Group
Sleep Cycle
Solar Foods
Spago Nanomedical
Svedbergs Group
Taaleri
Terranor
Vertiseit
Vivesto
W5 Solutions
Waystream
Sweden
Healthcare
Near term
6-12 MONTHS
Elicera’s near-term equity story is driven by clinical validation, with upcoming cohort readouts from the CARMA Phase I/IIa study the key catalyst. Data from additional cohorts is expected to further inform on safety, tolerability and early efficacy signals, which we believe is critical for de-risking the iTANK platform and supporting external interest. Beyond CARMA, and with increasing focus on ELC-401 in glioblastoma, the emphasis remains on strengthening the narrative around iTANK as a modular immune-enhancing platform applicable across multiple tumour types.
Long term
6+ YEARS
The success of CARMA is critical for Elicera, since it acts as a proof of concept in humans for the whole iTANK platform, which may in the end prove to be a springboard for development in solid tumours – a potentially significant opportunity in oncology, in our view. We believe Elicera’s long-term equity story is anchored in the scalability of the iTANK platform across multiple cell-therapy modalities. Over a five-year horizon, we expect value creation to be driven by the continued clinical maturation of the CARMA programme into later-stage development, expansion into additional indications (including ELC-401 in glioblastoma) and potential partnering or out-licensing of the iTANK platform to third-party CAR T/TCR T developers.
The most significant risk is related to clinical development – regulatory hurdles, potential delays and clinical trial failures
As an early clinical stage biotech, Elicera relies on external financing, and we believe it will require additional financing to complete CARMA as well as support operations as a whole and continue developing the pipeline
Partner dependence
Price
Fair range high value
Fair range low value
The upper end of our fair value range is derived from an SOTP analysis applying a WACC of 14%.The lower end reflects a WACC of 20%. Our SOTP includes the company’s key programmes ELC-301, ELC-401 and ELC-100, as well as the iTANK platform.
We value Elicera Therapeutics using a probability-adjusted cash flow model, evaluating each project individually and aggregating them in an SOTP model. Our valuation includes its lead assets ELC-301, ELC-401 and ELC-100, where we see a clear path forward, discounting future cash flows with a WACC of 14–20%. We also factor in the technology value of iTANK in our scenario analysis.
About DNB Carnegie Access
DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.
Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.
Private Banking
Tailored wealth management. Your financial future, personalized.
Montrose
A digital investment platform designed for passionate investors.
DNB Carnegie
Leading Nordic investment bank and wealth management.
© Copyright DNB Carnegie Investment Bank AB